Pharvaris N.V. (PHVS)

NMS – Real vaqt narxi. Valyuta: USD

36.46

+2.04 (5.93%)

Yopilishda: Aug 12, 2026, 4:00 PM EDT

36.25

-0.21 (-0.58%)

Bozordan keyin: Aug 12, 2026, 4:55 PM EDT

12.08.2026

Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update

ZUG, Switzerland, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema (AE-BK), such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced financial results for the second quarter ending on June 30, 2026, and provided a business update.

06.08.2026

Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology

ZUG, Switzerland, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema, such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that results from the first in-depth qualitative study assessing the experiences of people with AAE-C1INH and validating relevant patient-reported outcome (PRO) measures have been published in Frontiers in Immunology. The study findings directly informed the design of and endpoint selection for the ongoing Phase 3 CREAATE study (NCT07266805) investigating deucrictibant for the prophylaxis and on-demand treatment of AAE-C1INH attacks.

04.08.2026

Pharvaris: One Molecule Could Reshape Both Sides Of HAE Treatment

Pharvaris is positioned to build a vertically integrated HAE franchise with deucrictibant in both immediate-release (IR) and extended-release (XR) forms. PHVS's NDA for deucrictibant IR was accepted by the FDA, with a PDUFA date set for April 23, 2027, following strong Phase 3 RAPIDe-3 results. The CHAPTER-3 Phase 3 data for deucrictibant XR, expected Q3 2026, is the pivotal catalyst determining PHVS's potential as an end-to-end HAE platform.

Videolar

No Data

There is no data to display

Press-relizlar

12.08.2026

Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update

06.08.2026

Pharvaris N.V. (PHVS)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Pharvaris N.V. (PHVS)

Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update

Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology

Pharvaris: One Molecule Could Reshape Both Sides Of HAE Treatment

Videolar

No Data

Press-relizlar

Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update

Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology

Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update

Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology

Pharvaris: One Molecule Could Reshape Both Sides Of HAE Treatment

Videolar

No Data

Press-relizlar

Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update

Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology

Search stocks

Pharvaris N.V. (PHVS)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Pharvaris N.V. (PHVS)

Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update

Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology

Pharvaris: One Molecule Could Reshape Both Sides Of HAE Treatment

Videolar

No Data

Press-relizlar

Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update

Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology

Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update

Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology

Pharvaris: One Molecule Could Reshape Both Sides Of HAE Treatment

Videolar

No Data

Press-relizlar

Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update

Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology